Key Points
- Insider selling: EVP Lee Scott Golden sold 866 shares on Jan. 8 at an average $76.45 (worth $66,205.70) and also sold 1,340 and 642 shares on Jan. 6–7; multiple executives (including the CEO and CFO) disclosed open‑market sales Jan. 6–12 although they still retain large positions.
- At the J.P. Morgan conference PTC reported unaudited Q4 Sephience™ revenue of $92.5M, raised 2025 product & royalty revenue to ~ $823M (above guidance), issued 2026 product revenue guidance of $700–800M, and disclosed cash of about $1.94B.
- The company beat its recent quarterly estimates (EPS $0.20 vs. -$1.19 est.; revenue $211.0M vs. $177.4M) and carries mixed analyst coverage—nine Buys, seven Holds, one Sell—with an average target of $77.27.
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) EVP Lee Scott Golden sold 866 shares of the business's stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $76.45, for a total value of $66,205.70. Following the transaction, the executive vice president owned 92,428 shares of the company's stock, valued at $7,066,120.60. The trade was a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Lee Scott Golden also recently made the following trade(s):
- On Wednesday, January 7th, Lee Scott Golden sold 642 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total transaction of $49,742.16.
- On Tuesday, January 6th, Lee Scott Golden sold 1,340 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total transaction of $103,113.00.
PTC Therapeutics Stock Performance
Shares of NASDAQ PTCT opened at $77.59 on Tuesday. PTC Therapeutics, Inc. has a 52-week low of $35.95 and a 52-week high of $87.50. The stock has a market cap of $6.23 billion, a P/E ratio of 9.06 and a beta of 0.49. The firm has a 50 day moving average price of $76.81 and a 200 day moving average price of $63.11.
PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The company had revenue of $211.01 million for the quarter, compared to analysts' expectations of $177.42 million. During the same period last year, the firm posted ($1.39) earnings per share. The business's quarterly revenue was up 7.2% compared to the same quarter last year. Analysts predict that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.
Institutional Trading of PTC Therapeutics
A number of institutional investors have recently made changes to their positions in PTCT. Smartleaf Asset Management LLC grew its position in PTC Therapeutics by 101.3% in the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 236 shares in the last quarter. Optiver Holding B.V. boosted its stake in shares of PTC Therapeutics by 96.5% during the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 249 shares during the last quarter. Comerica Bank grew its holdings in shares of PTC Therapeutics by 868.5% in the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 469 shares in the last quarter. IFP Advisors Inc grew its holdings in shares of PTC Therapeutics by 68.1% in the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 310 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of PTC Therapeutics by 42.1% in the second quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 295 shares during the last quarter.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on PTCT shares. Weiss Ratings reaffirmed a "hold (c)" rating on shares of PTC Therapeutics in a research report on Monday, December 29th. The Goldman Sachs Group increased their target price on PTC Therapeutics from $44.00 to $50.00 and gave the stock a "sell" rating in a research note on Wednesday, November 5th. Citigroup lifted their price target on shares of PTC Therapeutics from $50.00 to $75.00 and gave the company a "neutral" rating in a research note on Wednesday, November 5th. Wall Street Zen upgraded shares of PTC Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, January 3rd. Finally, Barclays raised their price objective on shares of PTC Therapeutics from $46.00 to $68.00 and gave the stock an "equal weight" rating in a report on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $77.27.
Read Our Latest Research Report on PTCT
Key Stories Impacting PTC Therapeutics
Here are the key news stories impacting PTC Therapeutics this week:
- Positive Sentiment: PTC provided a detailed update at the J.P. Morgan conference saying Sephience™ (sepiapterin) continues to scale — unaudited Q4 global Sephience revenue of $92.5M, unaudited 2025 total product & royalty revenue of ~ $823M (above guidance), 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth), and cash of ~$1.94B. These results and the 2026 guidance are the main bullish catalysts for the stock today. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
- Positive Sentiment: PTC presented at the 44th Annual J.P. Morgan Healthcare Conference (transcript available), reinforcing commercial execution and management commentary that supports the guidance and growth story. Conference Transcript
- Neutral Sentiment: Reported short interest data shows 0 shares (appears to be a data anomaly / NaN change) and a 0.0 days-to-cover — likely not meaningful to trading given the company’s volume and recent volatility. (Source: market data entry)
- Negative Sentiment: Multiple insiders disclosed open‑market sales between Jan 6–12 (CEO Matthew B. Klein, CFO Pierre Gravier, VP Mark Boulding, EVP/other officers including Eric Pauwels, Christine Utter, Lee Golden, Neil Almstead). Individual sales ranged from several dozen to several thousand shares; the CEO and other executives still retain large positions. Insider selling can create short‑term caution among investors even when shares are sold in open‑market transactions. Key filings/articles: CEO Form 4 (SEC). CEO Form 4 Eric Pauwels Form 4 (SEC). Pauwels Form 4 Media summary of CFO/CEO sales. Insider Selling Article
About PTC Therapeutics
(
Get Free Report)
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.
Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
